The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $777,258 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to improve the understanding of heart failure in patients with hypertrophic cardiomyopathy (HCM).
The project aims to characterize the key pathophysiological mechanisms of heart failure symptoms in HCM using advanced cardiac MRI techniques, including evaluation of cardiac energetics, microvascular dysfunction, and exercise-induced cardiac function changes. The findings are expected to inform a more personalized approach to managing HCM patients, utilizing novel cardiac myosin inhibitor pharmacotherapies or established surgical treatments. The award period is from February 2025 through January 2030.
Generated 3/25/25, 2:45 AM